PRESS RELEASES
MediaPress Releases
See our recent news and announcements below. If you have any questions or for media inquiries, please contact info@pyramidbio.com for assistance or see specified media contact details within each release.
Pyramid Biosciences to Present at the B. Riley Securities Third Annual Oncology Conference
WALTHAM, MA, Thursday, January 19, 2023 -
Pyramid Biosciences, Inc., a privately-held, clinical-stage biotechnology company focused on developing new and highly differentiated precision therapies for cancer and other serious diseases, has announced its participation this week in the B. Riley Securities 3rd Annual Oncology Conference. Its Chief Executive Officer, Dr. Brian Lestini, will present on Thursday, January 19, 2023, at 2 PM ET.
Previous Press Releases
Pyramid Biosciences to Present at the B. Riley Securities Third Annual Oncology Conference
Pyramid Biosciences To Present at the 2022 Jefferies London Healthcare Conference
Pyramid Biosciences Names Biren Amin as Chief Financial and Strategy Officer
Pyramid Biosciences Names Nushmia Khokhar, MD, as Chief Medical Officer
Pyramid Biosciences Receives Orphan Drug Designation for PBI-200 From FDA
Pyramid Biosciences Appoints Brian Lestini, MD, PhD as Chief Executive Officer
Pyramid Biosciences Expands Precision Oncology Pipeline
Pyramid Biosciences Announces First Patients Dosed in Phase 1 Clinical Program for Dermatology
Pyramid Biosciences Announces Leadership Team Expansion
Pyramid Biosciences Secures $28 Million in Funding to Accelerate Clinical Programs